Literature DB >> 7891601

Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults.

J G Gerrard1.   

Abstract

OBJECTIVES: To identify patient populations at risk of Pneumocystis carinii pneumonia (PCP) and assess the potential role of chemoprophylaxis.
METHODS: Review of cases of PCP among patients admitted to a tertiary referral hospital in Sydney between January 1990 and April 1993. Cases were identified by indirect immunofluorescent antibody microscopy performed on respiratory tract specimens.
RESULTS: Ninety-two episodes of PCP were diagnosed in 64 HIV-positive patients and 28 others. All HIV-negative patients had received corticosteroids combined with other immunosuppressive agents before the onset of PCP symptoms, which occurred within six months of immunosuppression. The group included nine of 150 kidney transplant recipients (6%) six of 138 liver transplant recipients (4.3%) and three of 25 patients with Wegener's granulomatosis (12%). Mortality associated with PCP in HIV-negative patients was significantly higher than in those who were HIV-positive (32% v. 8%, P < 0.005).
CONCLUSION: Solid organ transplant recipients and individuals receiving treatment for Wegener's granulomatosis have a significant risk of developing PCP. Given the high mortality associated with this disease in HIV-negative patients, primary PCP chemoprophylaxis should be considered during the first six months of immunosuppression.

Entities:  

Mesh:

Year:  1995        PMID: 7891601     DOI: 10.5694/j.1326-5377.1995.tb139873.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  10 in total

Review 1.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

Review 3.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 4.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

5.  Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient.

Authors:  Jordan Y Z Li; Tuck Y Yong; David I Grove; P Toby H Coates
Journal:  Clin Exp Nephrol       Date:  2008-08-30       Impact factor: 2.801

6.  Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients.

Authors:  Lukas Ebner; Laura N Walti; Andri Rauch; Hansjakob Furrer; Alexia Cusini; Andreas M J Meyer; Stefan Weiler; Uyen Huynh-Do; Johannes Heverhagen; Spyridon Arampatzis; Andreas Christe
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

Review 7.  Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention.

Authors:  Evin Sowden; Andrew J Carmichael
Journal:  BMC Infect Dis       Date:  2004-10-16       Impact factor: 3.090

8.  Pneumocystis jiroveci outbreak in a renal transplant center: Lessons learnt.

Authors:  A Jairam; M Dassi; P Chandola; M Lall; D Mukherjee; A K Hooda
Journal:  Indian J Nephrol       Date:  2014-09

9.  Pneumocystis jirovecii pneumonia (PCP) PCR-negative conversion predicts prognosis of HIV-negative patients with PCP and acute respiratory failure.

Authors:  Ji Soo Choi; Sang Hoon Lee; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Moo Suk Park
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

10.  Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.

Authors:  Matthew L Basiaga; Michelle E Ross; Jeffrey S Gerber; Alexis Ogdie
Journal:  J Pediatric Infect Dis Soc       Date:  2018-12-03       Impact factor: 3.164

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.